
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Ipswich, U.K. -- From a ragbag of low-quality randomized trials, the simplest and cheapest topical preparation has emerged as the safest and most effective treatment of cutaneous warts, according to Sam Gibbs, M.R.C.P.